Kurin Inc., the innovative company behind the Kurin® blood culture collection sets, has announced the appointment of Christine Arme as Chief Commercial Officer. With a distinguished career spanning 35 years in the healthcare industry, Christine brings a wealth of experience from both start-up and scaled growth stage healthcare organisations, operating in both domestic and international capacities. Most recently, she served as the Vice President of Healthcare Systems at Solventum (formerly 3M Healthcare), where she led the Key Account organisation for the Medical Surgical business unit, the largest within Solventum.
Bob Rogers, CEO of Kurin, Inc., expressed his enthusiasm for Christine’s appointment, stating, “We are pleased to welcome Christine to Kurin. Her significant contributions to our success at Ivera Medical, the creators of the market-leading Curos Port Protector, which was acquired by 3M in 2015, are noteworthy. Her continued success and advancement in more senior roles have been impressive, and we are excited to have her rejoin our team. Kurin is poised for accelerated growth, and Christine’s skill, leadership, and energy are exactly what we need to achieve our next milestones.”
Christine Arme shared her excitement about reuniting with the Ivera Medical leadership team, saying, “It’s like coming home to a familiar family that exudes a strong culture and a mission to improve healthcare, reduce costs, and help clinicians and patients—all of which I am very passionate about.”
Kurin’s innovative approaches to addressing the issue of contaminated blood cultures are based on simple, intuitive designs that require no additional user steps. Their products, Kurin Lock and Kurin Jet, passively sideline potential contaminants during blood culture collection, significantly reducing the problem of false-positive results. This is crucial, as approximately one-third of positive blood culture results are incorrect, leading to unnecessary antibiotic use, extended hospital stays, and broader public health issues like antimicrobial resistance and C. diff. infections.
